Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1130874

Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness


Barun, Barbara; Gabelić, Tereza; Adamec, Ivan; Babić, Antonija; Lalić, Hrvoje; Batinić, Drago; Krbot Skorić, Magdalena; Habek, Mario
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness // Multiple Sclerosis and Related Disorders, 48 (2021), 102704, 5 doi:10.1016/j.msard.2020.102704 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1130874 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness

Autori
Barun, Barbara ; Gabelić, Tereza ; Adamec, Ivan ; Babić, Antonija ; Lalić, Hrvoje ; Batinić, Drago ; Krbot Skorić, Magdalena ; Habek, Mario

Izvornik
Multiple Sclerosis and Related Disorders (2211-0348) 48 (2021); 102704, 5

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
B cells ; COVID-19 ; delay ; multiple sclerosis ; ocrelizumab ; repopulation

Sažetak
Objective: To evaluate clinical and laboratory effects of delaying ocrelizumab infusions during the COVID-19 pandemics in people with multiple sclerosis (pwMS). Methods: We have retrospectively searched our electronic database and identified 33 pwMS who had a delay in treatment due to COVID-19 pandemics. The following data were extracted: age, sex, multiple sclerosis (MS) phenotype: relapsing-remitting (RRMS) or primary progressive multiple sclerosis (PPMS), disease duration, Expanded Disability Status scale (EDSS), previous disease modifying therapy (DMT), number of ocrelizumab cycles prior to the lockdown, dates of first ocrelizumab infusion, last ocrelizumab infusion prior to the lockdown and delayed ocrelizumab infusion after the lockdown. Flow cytometry results, relapses and EDSS progression prior to the delayed ocrelizumab infusion after the lockdown were extracted. Results: The mean time between two ocrelizumab infusion during the lockdown was 7.72±0.64 (range 6.07 to 8.92) months. The mean time between last ocrelizumab infusion and the lymphocyte sampling prior to post COVID infusion was 6.59±0.95 (range 5.18 to 8.49) months. In this period, none of the studied patients had a relapse. In a multivariable linear regression analysis, time from last ocrelizumab infusion to lymphocyte sampling prior to the next infusion was the only significant predictor for CD19+ B cells count, when corrected for the number of previous ocrelizumab cycles and MS phenotype (RRMS or PPMS) (B=7.981, 95% C.I. 3.277-12.686, p=0.002). Conclusions: We have not shown clinical consequences of delaying ocrelizumab due to COVID-19 pandemics. However, the delay in dosing of ocrelizumab was an independent predictor of repopulation of B cells.

Izvorni jezik
Engleski

Znanstvena područja
Kliničke medicinske znanosti



POVEZANOST RADA


Ustanove:
Fakultet elektrotehnike i računarstva, Zagreb,
Medicinski fakultet, Zagreb,
Klinički bolnički centar Zagreb

Citiraj ovu publikaciju

Barun, Barbara; Gabelić, Tereza; Adamec, Ivan; Babić, Antonija; Lalić, Hrvoje; Batinić, Drago; Krbot Skorić, Magdalena; Habek, Mario
Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness // Multiple Sclerosis and Related Disorders, 48 (2021), 102704, 5 doi:10.1016/j.msard.2020.102704 (međunarodna recenzija, članak, znanstveni)
Barun, B., Gabelić, T., Adamec, I., Babić, A., Lalić, H., Batinić, D., Krbot Skorić, M. & Habek, M. (2021) Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness. Multiple Sclerosis and Related Disorders, 48, 102704, 5 doi:10.1016/j.msard.2020.102704.
@article{article, year = {2021}, pages = {5}, DOI = {10.1016/j.msard.2020.102704}, chapter = {102704}, keywords = {B cells, COVID-19, delay, multiple sclerosis, ocrelizumab, repopulation}, journal = {Multiple Sclerosis and Related Disorders}, doi = {10.1016/j.msard.2020.102704}, volume = {48}, issn = {2211-0348}, title = {Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness}, keyword = {B cells, COVID-19, delay, multiple sclerosis, ocrelizumab, repopulation}, chapternumber = {102704} }
@article{article, year = {2021}, pages = {5}, DOI = {10.1016/j.msard.2020.102704}, chapter = {102704}, keywords = {B cells, COVID-19, delay, multiple sclerosis, ocrelizumab, repopulation}, journal = {Multiple Sclerosis and Related Disorders}, doi = {10.1016/j.msard.2020.102704}, volume = {48}, issn = {2211-0348}, title = {Influence of delaying ocrelizumab dosing in multiple sclerosis due to COVID-19 pandemics on clinical and laboratory effectiveness}, keyword = {B cells, COVID-19, delay, multiple sclerosis, ocrelizumab, repopulation}, chapternumber = {102704} }

Časopis indeksira:


  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font